KUALA LUMPUR: Shares of Yong Tai Bhd attracted strong trading interest in early trade Friday, rising over 9%.
The counter rose 9.43%, or 2.5 sen to 29 sen. It is currently the second most active counter on Bursa Malaysia with 182 million shares done.
Yong Tai’s subsidiary, YTB Healthcare Sdn Bhd (YTBH), has secured approval for the clinical trial import licence from the National Pharmaceutical Regulatory Agency (NPRA), allowing it to conduct Phase 3 clinical trials for Covid-19 vaccine in Malaysia.
It said the approval granted by NPRA to YTBH followed the earlier approval received from the Medical Review Ethics Committee (MREC).
Yong Tai said its strategic partner Shenzhen Kangtai Biological Products Co Ltd (SZKT) has been granted the emergency use authorisation (EUA) by the government of China recently for developing the inactivated Covid-19 vaccine (KCONVAC).
SZKT commenced its KCONVAC vaccination programme in China, with its first batch of vaccination programme of more than 500,000 doses on June 1.